Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 150

1.

Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV.

Bilal U, Lau B, Lazo M, McCaul ME, Hutton HE, Sulkowski MS, Moore RD, Chander G.

AIDS Patient Care STDS. 2016 May;30(5):200-7. doi: 10.1089/apc.2016.0010.

PMID:
27158847
2.

 Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Voss F, Gallivan JP, Böcher WO, Ferenci P, Ferenci P.

Ann Hepatol. 2016 May-Jun, 2016;15(3):333-349.

3.

Antimicrobial Access in the 21st Century: Delays and Critical Shortages.

Shoham S, Antar AA, Auwaerter PG, Durand CM, Sulkowski MS, Cotton DJ.

Ann Intern Med. 2016 Mar 22. doi: 10.7326/M15-3076. [Epub ahead of print] No abstract available.

PMID:
26999651
4.

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.

Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, Khatri A, Abunimeh M, Podsadecki T, Lawitz E.

Gastroenterology. 2016 Jun;150(7):1590-8. doi: 10.1053/j.gastro.2016.02.078. Epub 2016 Mar 11.

5.

Public health clinic-based hepatitis C testing and linkage to care in baltimore.

Falade-Nwulia O, Mehta SH, Lasola J, Latkin C, Niculescu A, O'Connor C, Chaulk P, Ghanem K, Page KR, Sulkowski MS, Thomas DL.

J Viral Hepat. 2016 May;23(5):366-74. doi: 10.1111/jvh.12507. Epub 2016 Feb 3.

PMID:
26840570
6.

Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India.

Solomon SS, Srikrishnan AK, McFall AM, Kumar MS, Saravanan S, Balakrishnan P, Solomon S, Thomas DL, Sulkowski MS, Mehta SH.

PLoS One. 2016 Jan 26;11(1):e0147879. doi: 10.1371/journal.pone.0147879. eCollection 2016.

7.

HCV-HIV co-infected patients: no longer a 'special' population?

Sulkowski MS.

Liver Int. 2016 Jan;36 Suppl 1:43-6. doi: 10.1111/liv.13021. Review.

PMID:
26725896
8.

Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.

Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, Gitlin N, Workowski K, Zhu Y, Yang JC, Pang PS, McHutchison JG, Muir AJ, Howell C, Kowdley K, Afdhal N, Reddy KR.

Hepatology. 2016 Feb;63(2):437-44. doi: 10.1002/hep.28334. Epub 2015 Dec 18.

9.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM; HCV-TARGET Study Group.

Gastroenterology. 2016 Feb;150(2):419-29. doi: 10.1053/j.gastro.2015.10.013. Epub 2015 Oct 21.

PMID:
26497081
10.

Extrahepatic morbidity and mortality of chronic hepatitis C.

Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP.

Gastroenterology. 2015 Nov;149(6):1345-60. doi: 10.1053/j.gastro.2015.08.035. Epub 2015 Aug 28. Review.

PMID:
26319013
11.

Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons.

Balagopal A, Barin B, Quinn J, Rogers R, Sulkowski MS, Stock PG.

PLoS One. 2015 Aug 27;10(8):e0135882. doi: 10.1371/journal.pone.0135882. eCollection 2015.

12.

Development of sofosbuvir for the treatment of hepatitis C virus infection.

Lawitz E, Jacobson IM, Nelson DR, Zeuzem S, Sulkowski MS, Esteban R, Brainard D, McNally J, Symonds WT, McHutchison JG, Dieterich D, Gane E.

Ann N Y Acad Sci. 2015 Nov;1358:56-67. doi: 10.1111/nyas.12832. Epub 2015 Jul 31. Review.

PMID:
26235748
13.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC Jr, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P; ALLY-2 Investigators.

N Engl J Med. 2015 Aug 20;373(8):714-25. doi: 10.1056/NEJMoa1503153. Epub 2015 Jul 21.

14.

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators.

Gastroenterology. 2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15.

15.

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.

Pol S, Sulkowski MS, Hassanein T, Gane EJ, Liu L, Mo H, Doehle B, Kanwar B, Brainard D, Subramanian GM, Symonds WT, McHutchison JG, Nahass RG, Bennett M, Jacobson IM.

Hepatology. 2015 Jul;62(1):129-34. doi: 10.1002/hep.27836. Epub 2015 May 20.

PMID:
25847509
16.

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T.

JAMA. 2015 Mar 24-31;313(12):1223-31. doi: 10.1001/jama.2015.1328.

PMID:
25706092
17.

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM.

Aliment Pharmacol Ther. 2015 Apr;41(7):671-85. doi: 10.1111/apt.13095. Epub 2015 Jan 28.

18.

Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.

Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, Celentano DD, Iqbal SH, Anand S, Vasudevan CK, Saravanan S, Lucas GM, Kumar MS, Sulkowski MS, Quinn TC.

Lancet Infect Dis. 2015 Jan;15(1):36-45. doi: 10.1016/S1473-3099(14)71045-X. Epub 2014 Dec 3.

19.

Management of acute and chronic HCV infection in persons with HIV coinfection.

Sulkowski MS.

J Hepatol. 2014 Nov;61(1 Suppl):S108-19. doi: 10.1016/j.jhep.2014.08.006. Epub 2014 Nov 3. Review.

20.

Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.

Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Blick G, Khatri A, Hu YB, Gibbons K, Fredrick L, Co M, D'Amico R, Da Silva-Tillmann B, Trinh R, Sulkowski MS.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19500. doi: 10.7448/IAS.17.4.19500. eCollection 2014.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk